ArticleCancer medicine2020
Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Risk-stratified surveillance after LEEP: a nomogram integrating HPV persistence, margin status, and clinical factors to predict CIN2+ recurrence.Frontiers in oncology · 2026Article
- Clinical epidemiology and associations between HPV infection and vaginal infections in Jinan, China: a cross-sectional analysis.Frontiers in cellular and infection microbiology · 2026Article
- Cytologic DNA methylation for managing minimally abnormal cervical cancer screening results.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- Prevalence and Genotype Distribution of Human Papillomavirus in 23,495 Cases in Guangzhou City, Guangdong Province, China.Current microbiology · 2025Article
- Nomogram prediction of the lymph-vascular space invasion in cervical cancer: comparison of 2009 and 2018 staging systems.Frontiers in oncology · 2025Article
- Assessment of Knowledge Gaps in Cervical Cancer Screening and HPV Vaccination Among Chinese Women: A Comprehensive Population-Based Study.Cancer management and research · 2025Article
- Impact of achieving WHO's 90-70-90 targets on cervical cancer elimination and potential benefits in preventing other HPV-related cancers in China: a modelling study.EClinicalMedicine · 2024Article
- CNKSR2 expression is correlated with immune infiltrates in Cervical Cancer as a favorable prognostic factor.Journal of Cancer · 2024Article
- The involvement of MALAT1-ALKBH5 signaling axis into proliferation and metastasis of human papillomavirus-positive cervical cancer.Cancer biology & therapy · 2023Article
- Article
- Knowledge, willingness, uptake and barriers of cervical cancer screening services among Chinese adult females: a national cross-sectional survey based on a large e-commerce platform.BMC women's health · 2023Article
- Characteristics of human papillomavirus infection among females and the genetic variations of HPV18 and HPV58 in Henan province, China.Scientific reports · 2023Article
- Genetic variability in the E6 and E7 oncogenes of HPV52 and its prevalence in the Taizhou area, China.Virology journal · 2022Article
- Prevalence and distribution of human papillomavirus (HPV) in Luoyang city of Henan province during 2015-2021 and the genetic variability of HPV16 and 52.Virology journal · 2022Article
- Cancer Burden in China during 1990-2019: Analysis of the Global Burden of Disease.BioMed research international · 2022Article
- Status quo and problem analysis of cervical cancer screening program in China: Based on RE-AIM framework.Frontiers in public health · 2022Article
- Prevalence and genotype distribution of human papillomavirus infection among women aged 30-65 years in Xi'an, China: a population-based study of 14,655 women.Human vaccines & immunotherapeutics · 2021Article
- HLA-G polymorphism impacts the outcome of oral HPV infections in women.BMC infectious diseases · 2021Article
- Quality evaluation of HPV vaccine-related online messages in China: a cross-sectional study.Human vaccines & immunotherapeutics · 2021Article
- Prevalence and genotype distribution of human papillomavirus among women with cervical lesions in Shenzhen city, China.Human vaccines & immunotherapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundHuman papillomavirus (HPV) attributable cancer burden is currently unknown in China, which is essential to evaluate the potential benefit of existing HPV vaccines and to inform cancer control policy.
methodsWe extracted data of cancer incidence and mortality in 2014 from Chinese Cancer Registry Annual Report, and data of national population from National Bureau of Statistics. HPV-attributable cancer burden was estimated by incorporating cancer rates and population forecasts by sex, cancer site, age and geographical area, and then combined to corresponding population attributable fractions.
resultsWe estimated that there were 110 894 HPV-attributable new cancer cases in China in 2014, including 99 253 cervical cancers, 4449 noncervical cancers in females and 7192 cancers in males. The age-standardized incidence of HPV-attributable cancers in China was 5.69 per 100 000 persons, being slightly higher in rural than urban areas. Specifically, 51.1% of HPV-attributable cervical cancers were diagnosed in women aged 40-54 years, while 75.8% of noncervical cancers were diagnosed at 45-79 years of age. Among males, 53.4% of cancers were diagnosed at 55-74 years of age. Thirty five thousand six hundred and eighty three HPV-attributable cancer deaths were estimated, including 29 683 due to cervical cancer, and 2307 and 3693 due to noncervical cancer in females and males, respectively.
conclusionsThe cancer burden attributable to HPV in China is substantial. HPV vaccination and cervical screening should be prioritized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.